Viking Therapeutics
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
    • Careers
  • Pipeline
    • Overview
    • Metabolic Disease Programs
      • VK2735 (Obesity, Metabolic Disorders)
      • VK2809 (NASH/MASH)
    • Rare Disease Program
      • VK0214 (X-ALD)
    • Other Pipeline Programs
      • VK5211 (Hip Fracture, Muscle Wasting)
      • VK0612 (Type 2 Diabetes)
      • VK1430 (Hypertriglyceridemia, NASH)
      • EPOR Agonist Program (Anemia)
  • Investors & Media
    • Overview
    • Stock Information
    • News & Events
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder Services
    • Corporate Presentation
  • Contact

Contact

Viking Therapeutics, Inc.

9920 Pacific Heights Blvd, Suite 350
San Diego, CA 92121
858-704-4660
General Information

Investors

Greg Zante
Chief Financial Officer
858-704-4672
gzante@vikingtherapeutics.com

Stephanie Diaz
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com

Media

Tim Brons
Vida Strategic Partners
646-319-8981
tbrons@vidasp.com

Business Development

BD@vikingtherapeutics.com

 

viking-therapeutics-map

 

 

viking therapeutics

About

Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.

VK5211

VK5211 is an orally available small molecule drug candidate with a differentiated mechanism of action.

Contact

General Information
Business Development
© Viking Therapeutics
Terms of Use
Privacy Policy

logo
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
    • Careers
  • Pipeline
    • Overview
    • Metabolic Disease Programs
      • VK2735 (Obesity, Metabolic Disorders)
      • VK2809 (NASH/MASH)
    • Rare Disease Program
      • VK0214 (X-ALD)
    • Other Pipeline Programs
      • VK5211 (Hip Fracture, Muscle Wasting)
      • VK0612 (Type 2 Diabetes)
      • VK1430 (Hypertriglyceridemia, NASH)
      • EPOR Agonist Program (Anemia)
  • Investors & Media
    • Overview
    • Stock Information
    • News & Events
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder Services
    • Corporate Presentation
  • Contact